Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
Seven plus eight makes six for Globus
The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.
Biohaven looks to seize a new opportunity
The post-Pfizer pipeline looks disparate, but the group insists there is a method to its fast-follower approach.
GSK’s tribulations continue
Two days ago GSK canned lete-cel. Now it is ditching otilimab, and daprodustat’s future is looking dicey.
Pepgen aims to overtake Sarepta
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.
ICNMD 2022 – still unclear whether Sarepta can accelerate
New data with SRP-9001 look decent, but filing plans remain uncertain.
